Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04JNI
|
||||
| Former ID |
DCL000414
|
||||
| Drug Name |
GSK2245840
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10:J40-J44, J47] | Phase 2 | [1] | ||
| Company |
GSK
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H30ClN5O2
|
||||
| Canonical SMILES |
CC1(CC(=O)N(C(=O)C1)CCCCN2CCN(CC2)C3=NC=CC=N3)C.Cl
|
||||
| InChI |
1S/C19H29N5O2.ClH/c1-19(2)14-16(25)24(17(26)15-19)9-4-3-8-22-10-12-23(13-11-22)18-20-6-5-7-21-18;/h5-7H,3-4,8-15H2,1-2H3;1H
|
||||
| InChIKey |
DGOCVISYYYQFEP-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | NAD-dependent deacetylase sirtuin-1 | Target Info | Modulator | [2], [3] | |
| KEGG Pathway | FoxO signaling pathway | ||||
| AMPK signaling pathway | |||||
| Glucagon signaling pathway | |||||
| Amphetamine addiction | |||||
| MicroRNAs in cancer | |||||
| PANTHER Pathway | p53 pathway | ||||
| Pathway Interaction Database | p73 transcription factor network | ||||
| Signaling events mediated by HDAC Class III | |||||
| E2F transcription factor network | |||||
| HIF-2-alpha transcription factor network | |||||
| Signaling events mediated by HDAC Class I | |||||
| FoxO family signaling | |||||
| Regulation of Androgen receptor activity | |||||
| Regulation of retinoblastoma protein | |||||
| Reactome | RORA activates gene expression | ||||
| Regulation of HSF1-mediated heat shock response | |||||
| Circadian Clock | |||||
| WikiPathways | Integrated Pancreatic Cancer Pathway | ||||
| SREBF and miR33 in cholesterol and lipid homeostasis | |||||
| Integrated Breast Cancer Pathway | |||||
| SREBP signalling | |||||
| Androgen receptor signaling pathway | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01154101) Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis. U.S. National Institutes of Health. | ||||
| REF 2 | Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin Investig Drugs. 2015 Mar;24(3):283-307. | ||||
| REF 3 | Sirtuin 1 activator SRT2104 protects Huntington's disease mice. Ann Clin Transl Neurol. 2014 Dec;1(12):1047-52. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.